Loading...
Loading chart...



The current price of YMAB is 0 USD — it has increased 0 % in the last trading day.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Wall Street analysts forecast YMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YMAB is7.98 USD with a low forecast of 3.00 USD and a high forecast of 8.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Y-mAbs Therapeutics Inc revenue for the last quarter amounts to 19.52M USD, decreased -14.36 % YoY.
Y-mAbs Therapeutics Inc. EPS for the last quarter amounts to -0.07 USD, decreased -66.67 % YoY.
Y-mAbs Therapeutics Inc (YMAB) has 107 emplpoyees as of February 08 2026.
Today YMAB has the market capitalization of 541.07M USD.